Point72 Asset Management L.P. Sells 1,055,762 Shares of LivaNova PLC (NASDAQ:LIVN)

Point72 Asset Management L.P. decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 50.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,036,248 shares of the company's stock after selling 1,055,762 shares during the period. Point72 Asset Management L.P. owned about 1.91% of LivaNova worth $47,989,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. KBC Group NV raised its stake in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after acquiring an additional 56,580 shares during the period. PNC Financial Services Group Inc. boosted its position in LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after purchasing an additional 1,424 shares during the period. Rhumbline Advisers boosted its position in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in LivaNova during the 4th quarter worth $2,772,000. Finally, Envestnet Asset Management Inc. increased its position in LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock worth $2,034,000 after buying an additional 5,850 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

LIVN stock traded down $0.43 during trading on Monday, reaching $43.97. 476,361 shares of the stock were exchanged, compared to its average volume of 645,674. The company has a market capitalization of $2.40 billion, a P/E ratio of 104.69 and a beta of 0.84. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $62.04. The stock has a 50 day simple moving average of $38.39 and a 200-day simple moving average of $44.81.

Wall Street Analyst Weigh In

Several research firms have recently commented on LIVN. Robert W. Baird upped their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.